Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy
Paolo Bidoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Davide Tassinari(University of Bologna), Rita Chiari(Azienda Ospedaliera di Perugia), Francesco Gelsomino(Azienda USL di Bologna), Francesco Grossi(University of Insubria), Claudia Proto(Fondazione IRCCS Istituto Nazionale dei Tumori), Cristina Noberasco(European Institute of Oncology), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Héctor Soto Parrà, Valeria Albanese(Ospedale Vincenzo Cervello), Marina Gilli(Ospedale Monaldi), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Annamaria Catino(Istituto Tumori Bari), Giovanni Maria Fadda(Università Cattolica del Sacro Cuore), Francesco Cognetti(National Cancer Institute), Lucia Bonomi, M.R. Migliorino(Nini Hospital), Giovanna Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 19
Related Papers
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
|The Lancet Oncology|2018|579
Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2010|454
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
|Annals of Oncology|2023|286